90/014,862USE OF DIAZOLIDINYL UREA FOR ANTI-CLUMPING OF BIOLOGICAL SAMPLES9,040,255Closed

Status

Reexamination Certificate Issued

Filed

Sep 17, 2021

Last Updated

May 25, 2022

Art Unit

3991

Requester

Unknown

Requested By

Third Party

Patent Owner

Biocept Inc.

P.O. Law Firm

Cooley, LLP

Sector (CPC)

GPhysics & Instruments
G01Measuring & Testing
G01NMaterial Analysis

USPC

435Chemistry: Molecular Biology And Microbiology

Reexam History (35 events)

May 27, 2022CCRDYApplication ready for PDX access by participating foreign offices
May 25, 2022REEXInput Issue Number and Issue Date for Reexamination
May 17, 2022RXPUBSReexam Forwarded to Office of Publications
May 12, 2022MRNRCRX - Mail Notice of Intent to Issue a Reexam Certificate
Apr 8, 2022RXLITSRReexam Litigation Search Conducted
Apr 7, 2022IDSCInformation Disclosure Statement considered
Mar 17, 2022RXA...Response after Non-Final Action
Feb 18, 2022MDEFTRX - Mail Notice of Defective Paper
Feb 7, 2022RXIDS.Information Disclosure Statement Filed
Feb 7, 2022WIDSInformation Disclosure Statement (IDS) Filed
Feb 7, 2022RXAF/DAffidavit(s), Declaration(s) and/or Exhibit(s) Filed
Dec 7, 2021MR.NFRX - Mail Reexam Non-Final Action
Nov 23, 2021NRX.Notice of Reexam Published in Official Gazette
Nov 17, 2021MREXORX - Mail Ex Parte Request for Reexamination Granted
Oct 4, 2021MRPWPRX - Mail Pilot Waiver Program - Ex Parte Interview Summary
Sep 30, 2021RXWVSTWaiver of owners statement in ex parte
Sep 23, 2021DOCKCase Docketed to Examiner in GAU
Sep 22, 2021MRXNReexamination Formalities Notice Mailed
Sep 22, 2021MRXNReexamination Formalities Notice Mailed
Sep 21, 2021FTFIFITF set to NO - revise initial setting
Sep 21, 2021RXPCOMCompletion of Preprocessing - Released to Assigned GAU
Sep 21, 2021RXTTLRPTTitle Report
Sep 21, 2021RXNREQAUNotice of assignment of reexamination request
Sep 21, 2021RXNREQFDNotice of reexamination request filing date
Sep 17, 2021BIG.Entity Status Set To Undiscounted (Initial Default Setting or Status Change)
Sep 17, 2021RXO_40Receipt of Orig. Ex Parte Reexam Request Less Than 40 Pages-Rule 1.20(c )(1)
Sep 17, 2021RXOSUB.RReexamination requested by third party requester
Sep 17, 2021WIDSInformation Disclosure Statement (IDS) Filed
Sep 17, 2021RXC/SRCertificate of Service
Sep 17, 2021IDSCInformation Disclosure Statement considered
Sep 17, 2021RXLET.Miscellaneous Incoming Letter
Sep 17, 2021RXLITSRReexam Litigation Search Conducted
Sep 17, 2021RXOSUB.RReexamination requested by third party requester
Sep 17, 2021RXAF/DRReexam - Affidavit(s), Declaration(s) and/or Exhibit(s) Filed by Third Party Requester
Sep 17, 2021RXIDS.RReexam - Information Disclosure Statement Filed by Third Party Requester

Prosecution, PTAB & CAFC

PTAB Proceedings (IPR, PGR, CBM, DER)

None found

Federal Circuit (CAFC)

None found

Terminal Disclaimer

None found

Prosecution History

None found

Maintenance Fees

Grant
May 26, 2015
3.5-yr
Nov 26, 2018
Paid Nov 26, 2018
7.5-yr
Nov 26, 2022
Paid Nov 28, 2022
11.5-yr
Nov 26, 2026
Expiry
Sep 23, 2031

Entity Status

Small Entity

Expires

Sep 23, 2031 (5.5 yr remaining)

Assignments

2012201320142015201620172018201920202021202220232024FiledSTEPHEN D. MIKOLAJCZYKPAVEL TSINBERGBIOCEPT, INC.PLUS THERAPEUTICS, INC.
AssignmentReel/Frame: 027344/0564Recorded: Dec 6, 2011

From

STEPHEN D. MIKOLAJCZYKInventor
Oct 22, 2011
PAVEL TSINBERGInventor
Oct 27, 2011

To

BIOCEPT, INC.

AssignmentReel/Frame: 067409/0214Recorded: May 14, 2024

From

BIOCEPT, INC.
Apr 19, 2024

To

PLUS THERAPEUTICS, INC.